Suppr
超能文献

Pseudoprogression and Immune-Related Response in Solid Tumors.

作者信息

Chiou Victoria L, Burotto Mauricio

机构信息

Center for Cancer Research, National Cancer Institute, Bethesda, MD.

Center for Cancer Research, National Cancer Institute, Bethesda, MD

出版信息

J Clin Oncol. 2015 Nov 1;33(31):3541-3. doi: 10.1200/JCO.2015.61.6870. Epub 2015 Aug 10.

DOI:10.1200/JCO.2015.61.6870

PMID:26261262

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4622096/

Abstract

摘要

相似文献

Pseudoprogression and Immune-Related Response in Solid Tumors.

J Clin Oncol. 2015 Nov 1;33(31):3541-3. doi: 10.1200/JCO.2015.61.6870. Epub 2015 Aug 10.

Immunotherapy in non-small cell lung cancer: The past, the present, and the future.

Thorac Cancer. 2019 Apr;10(4):585-586. doi: 10.1111/1759-7714.13012. Epub 2019 Feb 28.

Current status of immunotherapy.

Jpn J Clin Oncol. 2016 Mar;46(3):191-203. doi: 10.1093/jjco/hyv201. Epub 2016 Jan 26.

PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies.

Hum Pathol. 2017 Aug;66:13-33. doi: 10.1016/j.humpath.2017.06.012. Epub 2017 Jul 8.

The "value" of immune-checkpoint inhibitors for advanced lung cancer.

Respir Investig. 2017 Jul;55(4):253-254. doi: 10.1016/j.resinv.2017.04.001. Epub 2017 May 17.

Immunotherapy: pembrolizumab-is the writing on the wall for cancer?

Nat Rev Clin Oncol. 2015 Jul;12(7):371. doi: 10.1038/nrclinonc.2015.85. Epub 2015 May 12.

Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma.

Immunotherapy. 2016 Jun;8(6):677-9. doi: 10.2217/imt.16.6.

Nivolumab May Work as First-Line NSCLC Therapy.

Cancer Discov. 2016 Sep;6(9):OF2. doi: 10.1158/2159-8290.CD-NB2016-095. Epub 2016 Jul 27.

PD-1 Blockers.

Cell. 2015 Aug 27;162(5):937. doi: 10.1016/j.cell.2015.07.045.

Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches.

Lung Cancer. 2017 Apr;106:70-75. doi: 10.1016/j.lungcan.2017.02.002. Epub 2017 Feb 6.

引用本文的文献

Application of machine learning based on habitat imaging and vision transformer to predict treatment response of locally advanced esophageal squamous cell carcinoma following neoadjuvant chemoimmunotherapy: a multi-center study.

Front Immunol. 2025 Aug 6;16:1603249. doi: 10.3389/fimmu.2025.1603249. eCollection 2025.

Neoadjuvant chemoradiotherapy combined with immunotherapy: a promising strategy for MSS/pMMR locally advanced rectal cancer.

Med Oncol. 2025 Aug 13;42(10):428. doi: 10.1007/s12032-025-02918-8.

Interim C-reactive protein levels predict the prognosis of patients with metastatic colorectal cancer receiving immunotherapy: a retrospective cohort study.

Ther Adv Med Oncol. 2025 Aug 1;17:17588359251356581. doi: 10.1177/17588359251356581. eCollection 2025.

Complete Remission With Fourth-Line Immunotherapy After Chemotherapy Failure in a Lung Cancer Patient With Severe Autoimmune Disease: An Unexpected Turn in Oncologic Management.

Cureus. 2025 Jun 16;17(6):e86116. doi: 10.7759/cureus.86116. eCollection 2025 Jun.

Tumor-suppressing multi-enterobacteria and PD-1/PD-L1 immune checkpoint inhibitor combination improves the outcome of hepatocellular carcinoma therapy.

Front Immunol. 2025 Jun 20;16:1598436. doi: 10.3389/fimmu.2025.1598436. eCollection 2025.

[Ga]Ga-interleukin-2 for imaging activated T-lymphocytes: biochemical characterization and phase I study in normal subjects.

Eur J Nucl Med Mol Imaging. 2025 Jul 1. doi: 10.1007/s00259-025-07430-9.

Dynamic Alteration of HALP Score as a Predictor in Patients with Receiving Immunotherapy for Advanced Non-Small Cell Lung Cancer.

Medicina (Kaunas). 2025 May 27;61(6):989. doi: 10.3390/medicina61060989.

Monitoring Pseudoprogression Using Circulating Small Extracellular Vesicles Expressing PD-L1 in a Melanoma Patient Treated With Immune Checkpoint Inhibitors.

J Extracell Biol. 2025 Jun 22;4(6):e70066. doi: 10.1002/jex2.70066. eCollection 2025 Jun.

NeoPred: dual-phase CT AI forecasts pathologic response to neoadjuvant chemo-immunotherapy in NSCLC.

J Immunother Cancer. 2025 May 31;13(5):e011773. doi: 10.1136/jitc-2025-011773.

Clinical benefit of continuation of PD-1 inhibitors after progression on first-line chemoimmunotherapy in metastatic gastric cancer and biomarker exploration.

BMC Cancer. 2025 May 24;25(1):935. doi: 10.1186/s12885-025-14286-7.

本文引用的文献

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

Lancet Oncol. 2015 Apr;16(4):375-84. doi: 10.1016/S1470-2045(15)70076-8. Epub 2015 Mar 18.

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

Lancet Oncol. 2015 Mar;16(3):257-65. doi: 10.1016/S1470-2045(15)70054-9. Epub 2015 Feb 20.

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.

J Clin Oncol. 2015 May 1;33(13):1430-7. doi: 10.1200/JCO.2014.59.0703. Epub 2014 Dec 1.

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Nature. 2014 Nov 27;515(7528):563-7. doi: 10.1038/nature14011.

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.

Nature. 2014 Nov 27;515(7528):558-62. doi: 10.1038/nature13904.

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

Lancet. 2014 Sep 20;384(9948):1109-17. doi: 10.1016/S0140-6736(14)60958-2. Epub 2014 Jul 15.

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

J Clin Oncol. 2014 Apr 1;32(10):1020-30. doi: 10.1200/JCO.2013.53.0105. Epub 2014 Mar 3.

Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.

J Clin Oncol. 2013 Dec 1;31(34):4311-8. doi: 10.1200/JCO.2013.51.4802. Epub 2013 Oct 21.

Nivolumab plus ipilimumab in advanced melanoma.

N Engl J Med. 2013 Jul 11;369(2):122-33. doi: 10.1056/NEJMoa1302369. Epub 2013 Jun 2.

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

N Engl J Med. 2013 Jul 11;369(2):134-44. doi: 10.1056/NEJMoa1305133. Epub 2013 Jun 2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Suppr超能文献

Pseudoprogression and Immune-Related Response in Solid Tumors.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译